Kelun-Biotech

Merck Ends Some ADC Development with Kelun

Merck Drops Two Cancer ADCs from Kelun Deal, Focuses on Daiichi Sankyo

Anika Sharma

Merck & Co. is refining its strategy in the realm of antibody-drug conjugates (ADCs). Shortly after a $4 billion acquisition ...